Menu
Search
|

Menu

Close
X

Curis Inc CRIS.OQ (NASDAQ Stock Exchange Global Market)

1.75 USD
-0.15 (-7.89%)
As of 1:30 AM IST
chart
Previous Close 1.90
Open 1.89
Volume 49,398
3m Avg Volume 102,745
Today’s High 1.94
Today’s Low 1.75
52 Week High 11.35
52 Week Low 1.57
Shares Outstanding (mil) 163.88
Market Capitalization (mil) 263.85
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
10
FY16
8
FY15
8
EPS (USD)
FY18
-0.325
FY17
-1.816
FY16
-2.278
FY15
-2.531
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
31.74
5.73
Price to Book (MRQ)
vs sector
25.10
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
475.56
16.72
LT Debt to Equity (MRQ)
vs sector
432.96
12.39
Return on Investment (TTM)
vs sector
-124.16
14.61
Return on Equity (TTM)
vs sector
-250.87
16.34

EXECUTIVE LEADERSHIP

James McNab
Independent Chairman of the Board, Since 2002
Salary: --
Bonus: --
Ali Fattaey
President, Chief Executive Officer, Director, Since 2014
Salary: $527,677.00
Bonus: --
James Dentzer
Chief Financial Officer, Chief Operating Officer, Chief Administrative Officer, Since 2018
Salary: $320,846.00
Bonus: --
Robert Martell
Head - Research and Development, Since 2018
Salary: --
Bonus: --
David Tuck
Chief Medical Officer, Since 2016
Salary: $371,308.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4 Maguire Rd
LEXINGTON   MA   02421-3112

Phone: +1617.5036500

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

SPONSORED STORIES